Press Releases May 18, 2026 04:15 PM

Certara to Participate in Upcoming Investor Conferences

Certara announces participation in multiple upcoming investor conferences with live webcasts.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CERT

Certara, Inc., a leader in model-informed drug development, will participate in several investor conferences including RBC CM Global Healthcare, William Blair’s Growth Stock, and Jefferies Global Healthcare Conferences. The company will provide live webcasts of select events accessible through its investor relations website.

Certara to Participate in Upcoming Investor Conferences
CERT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Certara engages actively with investors through scheduled participation in prominent healthcare and growth stock conferences.
  • Live webcasts available for select conference presentations, improving transparency and investor communication.
  • The company positions itself as a global leader in biosimulation software and services for drug development, serving a broad client base across biopharmaceutical firms, academia, and regulatory bodies.

RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:

  • RBC CM Global Healthcare Conference
    Date and Time: Tuesday, May 19 at 9:30 a.m. ET
  • William Blair’s 46th Annual Growth Stock Conference
    Date: Tuesday, June 2
  • Jefferies Global Healthcare Conference
    Date: Wednesday, June 3 at 1:20 p.m. ET

Live webcasts for the RBC and Jefferies conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
[email protected]

Media Contact:
Alyssa Horowitz
[email protected]


Risks

  • Market and investor response to conference presentations may be uncertain and could impact stock volatility.
  • The company's performance is highly dependent on the pharmaceutical and healthcare sectors, which can be affected by regulatory changes and market competition.
  • Technology advancements or disruptions in biosimulation and drug development could impact Certara's competitive position.

More from Press Releases

Trump Media Settles Legal Disputes Jul 19, 2026 GEnx-1B Engines Surpass 50 Million Flight Hours Jul 19, 2026 XA Investments President Kimbery Flynn Speaks to Shareholders About XFLT Proxy Vote Jul 19, 2026 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population Jul 18, 2026 UFC Names Meridian Holdings Official Sponsor of Fight Night Belgrade Jul 18, 2026